- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1752 |
Product Name |
ADT1752-Human Anti-CD3xCEACAM5 Bispecific Antibody |
Isotype |
Human IgG1-kappa/lambda with domain crossover, trivalent |
Clonity |
Monoclonal |
|
Alternate Names Human Anti-CD3 mAb, Anti-CD3 Monoclonal Antibody, CD3 recombinant antibody, Anti-CD3 Bispecific Antibody, Human Anti-CEACAM5 mAb, CEACAM5 recombinant antibody, Anti-CEACAM5 Monoclonal Antibody, Anti-CEACAM5 Bispecific Antibody |
|
Official Symbol |
CD3xCEACAM5 |
Target 1 |
CD3 |
Gene ID 1 |
916 |
Target 2 |
CEACAM5 |
Gene ID 2 |
1048 |
Species |
Human |
Drug Name |
Cibisatamab |
Endotoxin |
<1EU/mg. Determined by the LAL method. |
Sterility |
0.2 μM filtered. |
Expression Host |
CHO Cells |
CAS Number |
2101242-53-7 |
Size |
1mg,5mg,50mg,100mg |
Research Area |
Cancer |
Application |
FuncS |
Purity |
>90% |
Concentration |
Batch dependent |
Buffer |
Supplied in PBS, pH 7.4,Contains no stabilizers or preservatives |
Recommended Dilution Buffer |
ABDB-1002 or PBS, pH 7.4, Contains no stabilizers or preservatives. |
Storage |
2 weeks, 2-8℃ under sterile conditions after reconstitution. Avoid repeated freeze-thaw. -80°C for one-year storage. |
Shipping Condition |
Shipped on ice packs. |
Protocol Information |
Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose-response or titration experiment. |
Note |
For Research Use Only! |
|
Reference 1. Weiss et al. (1986). Cell. DOI: 10.1016/0092-8674(86)90478-1
2. Hammarström et al. (1998). Tumour Biol. DOI: 10.1159/000030001
3. Smith-Garvin et al. (2009). Annu Rev Immunol. DOI: 10.1146/annurev.immunol.021908.132710
4. Duffy et al. (2010). Clin Cancer Res. DOI: 10.1158/1078-0432.CCR-09-1916
|
FAQ
-
+ -
What role does CEACAM5 play in cancer?
CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) is an oncofetal protein highly expressed in colorectal, gastric, and lung cancers. It is a promising target for antibody-drug conjugates (ADCs) and bispecific antibodies.
-
+ -
How can I obtain COA of the reagent that I received?
Please contact us via email info@alphalifetech.com for detailed information about the product.
-
+ -
What are the advantages of targeting CEACAM5 in solid tumors?
Since CEACAM5 is overexpressed in tumors but has limited normal tissue expression, it offers a selective therapeutic target. ADCs and immunotherapies targeting CEACAM5 aim to minimize toxicity while effectively killing tumor cells. -
+ -
What future trends are shaping bispecific antibody development?
Trends include multi-specific antibodies (>2 targets), improved tissue penetration, "off-the-shelf" formats, and combinations with CAR-T, vaccines, or small molecules.